Peptides with anticancer use or potential.
This review is an attempt to illustrate the diversity of peptides reported for a potential or an established use in cancer therapy. With 612 references, this work aims at covering the patents and publications up to year 2000 with many inroads in years 2001-2002. The peptides are classed according to four categories of effective (or plausible) biological mechanisms of action: receptor-interacting compounds; inhibitors of protein-protein interaction; enzymes inhibitors; nucleic acid-interacting compounds. The fifth group is made of the peptides for which no mechanism of action has been found yet. Incidentally this work provides an overview of many of the modern targets of anticancer research.
Janin
Y L
YL
UMR 176 CNRS-Intitut Curie, Paris, France. yves.janin@curie.u-psud.fr
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy*; D009696:Nucleic Acids / Q000378:metabolism; D010455:Peptides / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D015398:Signal Transduction / Q000502:physiology
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009696:Nucleic Acids; D010455:Peptides